Clinical Trial Update: A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Tasisulam-sodium to paclitaxel in metastatic melanoma was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Tasisulam-sodium (tasisulam)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Melanoma | Phase 3 | Status: TERMINATED | Results posted: 2018-07-17